文献速递神经肿瘤

难治性脑膜瘤术语的概念、意图与评估

The concept, intention, and evaluation of the term treatment-refractory meningioma.
PubMed 文献 · J Neurooncol · 2025-08-04

本研究系统综述69项研究并分析15个队列(n=211)的个体数据,评估接受SSTR靶向治疗的难治性脑膜瘤患者异质性。发现难治性定义差异大,WHO-1患者研究间异质性高(进展I²=81.7%,死亡I²=74.8%),WHO-2/3较一致(I²≤16.0%)。跨WHO级别合并不可行,提出四类建议改善一致性。

要点

  • 难治性脑膜瘤定义缺乏标准化,导致研究间异质性显著。
  • WHO-1患者SSTR靶向治疗效应估计异质性高,不宜跨级别合并。
  • 建议从影像评估、终点、临床核心要素和分子分类四方面统一标准。

核心结论

  • 难治性脑膜瘤术语使用不一致,效应估计随队列变异大,跨WHO级别合并不可行。

研究设计与样本

  • 系统综述69项2024年前发表的研究,分析15个队列(n=211)接受SSTR靶向治疗的难治性患者的个体数据,并以新诊断WHO-3脑膜瘤参考队列(n=102)作描述性比较。

主要发现

  • 难治性定义在研究间差异大。
  • WHO-1患者进展和死亡的研究间异质性高(I²=81.7%和74.8%),尤其在长效SSTR类似物组。
  • WHO-2和WHO-3患者跨终点和SSTR靶向治疗的异质性较低(I²≤16.0%)。
  • 进展和死亡风险按WHO级别显著不同,与SSTR靶向治疗无关。

关键数值与推荐

  • WHO-1患者进展I²=81.7%,死亡I²=74.8%(长效SSTR类似物组)。
  • WHO-2和WHO-3患者I²百分比≤16.0%。

临床怎么用

  • 未来试验设计应遵循影像评估、终点、临床核心要素和分子分类四类建议,避免跨WHO级别合并患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-refractory meningioma is a widely used term but lacks standardized criteria, impairing research comparability and treatment evaluation. The aim of this study was to assess the heterogeneity of patient populations labeled as treatment-refractory and to explore recommendations for better consistency. METHODS: We systematically reviewed 69 studies published before 2024 and analyzed individual participant data from 15 cohorts (n = 211) that included treatment-refractory patients who underwent experimental therapy with somatostatin receptor (SSTR)-targeted therapies. A reference cohort (n = 102) with newly diagnosed WHO-3 meningiomas was used descriptively for comparison. Progression and death were the primary endpoints. Hazard rate ratios were estimated via Poisson regression, and inter-study heterogeneity was quantified using I² statistics. RESULTS: Definitions of treatment-refractory varied substantially across previous studies. WHO-1 patients showed high statistical inter-study variability, particularly for the long-acting SSTR-analogues group when assessing progression (I² = 81.7%) and death (I² =74.8%). Patients with treatment-refractory WHO-2 and WHO-3 meningioma exhibited more consistency across endpoints and SSTR-targeted therapies (I² percentages ≤ 16.0%). Risk of progression and death differed significantly by WHO grade, regardless of SSTR-targeted therapy. CONCLUSIONS: Our findings demonstrate an inconsistent use of the term treatment-refractory and substantial variability of effect estimates dependeing on the individual cohorts. Pooling patients across WHO grades is unfeasible for assessing treatment effects. Based on the present study and prior evidence, we outline recommendations to improve consistency in future trial design and enable more meaningful comparisons across studies. The recommendations are grouped into four categories: radiographic evaluation, endpoints, clinical core elements, and molecular classification.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jensen LR, Maier AD, Juratli TA, et al. The concept, intention, and evaluation of the term treatment-refractory meningioma. J Neurooncol. 2025. PMID: 40760312. doi:10.1007/s11060-025-05154-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。